Geode Capital Management LLC Purchases 489,041 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Geode Capital Management LLC boosted its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 5.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,281,052 shares of the company's stock after purchasing an additional 489,041 shares during the quarter. Geode Capital Management LLC owned 0.82% of Teva Pharmaceutical Industries worth $203,642,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB bought a new position in Teva Pharmaceutical Industries during the 3rd quarter worth $50,000. Ameliora Wealth Management Ltd. acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $66,000. IFP Advisors Inc increased its stake in Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after acquiring an additional 1,960 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $104,000. Finally, Assetmark Inc. lifted its stake in Teva Pharmaceutical Industries by 1,370.3% during the fourth quarter. Assetmark Inc. now owns 5,205 shares of the company's stock worth $115,000 after purchasing an additional 4,851 shares during the last quarter. Institutional investors own 54.05% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on TEVA shares. Barclays decreased their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. UBS Group lowered their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday, January 30th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Friday, April 4th. Piper Sandler upped their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. Finally, Bank of America dropped their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of "Moderate Buy" and an average target price of $23.43.

Teva Pharmaceutical Industries Trading Up 4.7 %

NYSE:TEVA traded up $0.60 during mid-day trading on Friday, hitting $13.42. 12,222,912 shares of the company's stock were exchanged, compared to its average volume of 9,939,000. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The company has a 50 day simple moving average of $15.79 and a 200-day simple moving average of $17.82. The firm has a market capitalization of $15.22 billion, a P/E ratio of -9.26, a PEG ratio of 1.44 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.